Patents by Inventor Michael MATHO

Michael MATHO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED TNF AS A CAPTURE LIGAND
    Publication number: 20240252732
    Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 1, 2024
    Inventors: Michael MATHO, Steven F. JOSEPHS, Annette MARLEAU
  • Modified TNF as a capture ligand
    Patent number: 11957825
    Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 16, 2024
    Assignee: IMMUNICOM INC.
    Inventors: Michael Matho, Steven F. Josephs, Annette Marleau
  • MODIFIED TNF AS A CAPTURE LIGAND
    Publication number: 20220409795
    Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.
    Type: Application
    Filed: June 17, 2022
    Publication date: December 29, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Michael MATHO, Steven F. JOSEPHS, Annette MARLEAU